In vitro susceptibility to anticancer agents of the human KB carcinoma cell line transfected with COX-2 cDNA

Oncology Reports

Volumn 20, Issue 3, 2008, Pages 645-649

  Takaoka, Kazuki ^a   Kishimoto, Hiromitsu ^a   Segawa, Emi ^a   Otsu, Nao ^a   Zushi, Yusuke ^a   Hashitani, Susumu ^a   Noguchi, Kazuma ^a   Urade, Masahiro ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Cisplatin; Cyclooxygenase 2; Human KB carcinoma

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOOXYGENASE 2; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NEOMYCIN; SMALL INTERFERING RNA; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; COMPLEMENTARY DNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; PTGS2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CLONE; CELL STRAIN KB; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; LIPOSOMAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; WESTERN BLOTTING; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLEOMYCIN; BLOTTING, WESTERN; CELL PROLIFERATION; CISPLATIN; CYCLOOXYGENASE 2; DNA, COMPLEMENTARY; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KB CELLS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RNA, SMALL INTERFERING; TRANSFECTION; VINCRISTINE;

EID: 54549110001     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000054     Document Type: Article

References (33)

1. Vane J: Towards a better aspirin. Nature 367: 215-216, 1994.
2. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA and Jothy S: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55: 2556-2559, 1995.
3. Ristimaki A, Honkanen N, Jankala H, Sipponen P and Harkonen M: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57: 1276-1280, 1997.
4. Parrett ML, Harris R, Joarder FS, Ross MS, Clausen KP and Robertson FM: Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 10: 503-507, 1997.
5. Hida T, Yatabe Y, Achiwa H, et al: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58: 3761-3764, 1998.
6. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE and Schror K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59: 198-204, 1999.
7. Tucker ON, Dannenberg AJ, Yang EK, et al: Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59: 987-990, 1999.
8. Shirahama T: Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 6: 2424-2430, 2000.
9. Yoshimura R, Sano H, Masuda C, et al: Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89: 589-596, 2000.
10. Muller-Decker K, Scholz K, Marks F and Furstenberger G: Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis. Mol Carcinog 12: 31-41, 1999.
11. Takaoka K, Kishimoto H, Segawa E, et al: Elevated cell migration, invasion and tumorigenicity in human KB carcinoma cells transfected with COX-2 cDNA. Int J Oncol 29: 1095-1101, 2006.
12. Kollmannsbeger C, Nichols C and Bokemeyer C: Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer 106: 1217-1226, 2006.
13. Boulikas T and Vougiouka M: Cisplatin and platinum drug at the molecular level. Oncol Rep 10: 1163-1182, 2003.
14. Eagle H: Propagation in a fluid medium of a human epidermoid carcinoma, strain KB. Proc Soc Exp Biol Med 89: 362-364, 1995.
15. Tatebe S, Sinicrope FA and Kuo MT: Induction of multidrug resistance proteins MRP1 and MRP3 and γ-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun 290: 1427-1433, 2002.
16. Kishimoto H, Wang Z, Bhat-Nakshatri P, Chang D, Clarke R and Nakshatri H: The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1α/CXCL12. Carcinogenesis 26: 1706-1715, 2005.
17. Hashitani S, Urade M, Nishimura N, et al: Apoptosis induction enhancement of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head neck carcinoma cell lines. Int J Oncol 23: 665-672, 2003.
18. Takahashi M and Wakabayashi K: Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci 95: 475-480, 2004.
19. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H and Ristimaki A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58: 4997-5001, 1998.
20. Mohammed SI, Knapp DW, Bostwick DG, et al: Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 59: 5647-5650, 1999.
21. Torky A, Raemisch A, Glahn F and Foth H: Arachidonic acid pathway activates multidrug resistance related protein in cultured human lung cells. Arch Toxicol (In press).
22. Ziemann C, Schafer D, Rudell G, et al: The cyclooxygenase system participates in functional mdr1b overexpression in primary rat hepatocyte cultures. Hepatology 35: 579-588, 2002.
23. Patel VA, Dunn MJ and Sorokin A: Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 277: 38915-38920, 2002.
24. Ratnasinghe D, Daschner PJ, Anver MR, et al: Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res 21: 2141-2147, 2001.
25. Touhey S, O'Connor R, Plunkett S, Maguire A and Clynes M: Structure-activity relationship of indomethacin analogues for MRP-1, COX-1 and COX-2 inhibition. Identification of novel chemotherapeutic drug resistance modulators. Eur J Cancer 38: 1661-1670, 2002.
26. Dimberg J, Hugander A, Sirjo A and Soderkvist P: Enhanced expression of cyclooxygenase-2 and nuclear beta-catenin are related to mutations in the gene in human colorectal cancer. Anticancer Res 21: 911-915, 2001.
27. Saikawa Y, Sugiura T, Toriumi F, et al: Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15. Anticancer Res 24: 2723-2728, 2004.
28. Matsumoto S, Tanaka T, Kurokawa H, Matsuno K, Hayashida Y and Takahashi T: Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin. Anticancer Res 27: 2209-2216, 2007.
29. O'Connor R: The pharmacology of cancer resistance. Anticancer Res 27: 1267-1272, 2007.
30. Ishikawa T, Nakagawa H and Kuo MT: The GS-X pump/multidrug resistance protein (MRP): Role of gluthathion in their function and regulation. Nova Scotia Review (In press).
31. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T and Kawakami M: A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56: 4124-4129, 1996.
32. Katano K, Kondo A, Safaei R, et al: Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62: 6559-6565, 2002.
33. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.